JP2018537962A5 - - Google Patents

Download PDF

Info

Publication number: JP2018537962A5
Authority: JP; Japan
Prior art keywords: seq; antibody; antigen; binding portion; heavy chain
Prior art date: 2016-10-21
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

JP2018520536A

Other languages

English (en)

Japanese (ja)

Other versions

JP7030689B2 (ja

JP2018537962A (ja

Filing date

2016-10-21

Publication date

2019-11-28

2016-10-21 Application filed filed Critical

2016-10-21 Priority claimed from PCT/US2016/058249 external-priority patent/WO2017070561A1/en

2018-12-27 Publication of JP2018537962A publication Critical patent/JP2018537962A/ja

2019-11-28 Publication of JP2018537962A5 publication Critical patent/JP2018537962A5/ja

2022-03-07 Application granted granted Critical

2022-03-07 Publication of JP7030689B2 publication Critical patent/JP7030689B2/ja

Status Active legal-status Critical Current

2036-10-21 Anticipated expiration legal-status Critical

Links

239000000427 antigen Substances 0.000 claims description 52
102000036639 antigens Human genes 0.000 claims description 52
108091007433 antigens Proteins 0.000 claims description 52
101001002657 Homo sapiens Interleukin-2 Proteins 0.000 claims description 33
210000004027 cell Anatomy 0.000 claims description 14
125000003275 alpha amino acid group Chemical group 0.000 claims description 13
108020004707 nucleic acids Proteins 0.000 claims description 12
102000039446 nucleic acids Human genes 0.000 claims description 12
150000007523 nucleic acids Chemical class 0.000 claims description 12
238000000034 method Methods 0.000 claims description 9
102000055277 human IL2 Human genes 0.000 claims description 7
239000002773 nucleotide Substances 0.000 claims description 7
125000003729 nucleotide group Chemical group 0.000 claims description 7
206010062016 Immunosuppression Diseases 0.000 claims description 6
230000001506 immunosuppresive effect Effects 0.000 claims description 6
230000004968 inflammatory condition Effects 0.000 claims description 6
238000012258 culturing Methods 0.000 claims description 4
239000003937 drug carrier Substances 0.000 claims description 4
239000000546 pharmaceutical excipient Substances 0.000 claims description 4
239000008194 pharmaceutical composition Substances 0.000 claims description 3
208000023275 Autoimmune disease Diseases 0.000 claims description 2
208000009329 Graft vs Host Disease Diseases 0.000 claims description 2
108010002350 Interleukin-2 Proteins 0.000 claims description 2
102000000588 Interleukin-2 Human genes 0.000 claims description 2
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 2
239000004472 Lysine Substances 0.000 claims description 2
206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 2
210000004899 c-terminal region Anatomy 0.000 claims description 2
208000024908 graft versus host disease Diseases 0.000 claims description 2
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 2
210000004962 mammalian cell Anatomy 0.000 claims description 2
239000000203 mixture Substances 0.000 claims description 2
108010047041 Complementarity Determining Regions Proteins 0.000 claims 6
108091028043 Nucleic acid sequence Proteins 0.000 claims 1
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 5
230000001105 regulatory effect Effects 0.000 description 4
210000001744 T-lymphocyte Anatomy 0.000 description 3
230000006698 induction Effects 0.000 description 2
230000001939 inductive effect Effects 0.000 description 2
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
102100027581 Forkhead box protein P3 Human genes 0.000 description 1
101000861452 Homo sapiens Forkhead box protein P3 Proteins 0.000 description 1
101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 1
102000001712 STAT5 Transcription Factor Human genes 0.000 description 1
108010029477 STAT5 Transcription Factor Proteins 0.000 description 1
238000003556 assay Methods 0.000 description 1
239000003814 drug Substances 0.000 description 1
230000000694 effects Effects 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
210000000822 natural killer cell Anatomy 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1

JP2018520536A 2015-10-23 2016-10-21 抗ｉｌ－２抗体ならびにその組成物及び使用 Active JP7030689B2 (ja)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US201562245600P	2015-10-23	2015-10-23
US62/245,600		2015-10-23
US201662408360P	2016-10-14	2016-10-14
US62/408,360		2016-10-14
PCT/US2016/058249 WO2017070561A1 (en)	2015-10-23	2016-10-21	Anti-il-2 antibodies and compositions and uses thereof

Publications (3)

Publication Number	Publication Date
JP2018537962A JP2018537962A (ja)	2018-12-27
JP2018537962A5 true JP2018537962A5 (2)	2019-11-28
JP7030689B2 JP7030689B2 (ja)	2022-03-07

Family

ID=57233907

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2018520536A Active JP7030689B2 (ja)	2015-10-23	2016-10-21	抗ｉｌ－２抗体ならびにその組成物及び使用

Country Status (9)

Country	Link
US (4)	US10138298B2 (2)
EP (1)	EP3365369A1 (2)
JP (1)	JP7030689B2 (2)
KR (2)	KR102876923B1 (2)
CN (2)	CN115636880A (2)
AU (2)	AU2016340989B2 (2)
CA (1)	CA2946113A1 (2)
TW (1)	TW201722989A (2)
WO (1)	WO2017070561A1 (2)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR102876923B1 (ko)	2015-10-23	2025-10-28	화이자 인코포레이티드	항-il-2 항체 및 조성물 및 이의 용도
EP3448987A4 (en)	2016-04-29	2020-05-27	Voyager Therapeutics, Inc.	COMPOSITIONS FOR TREATING A DISEASE
EP3448874A4 (en)	2016-04-29	2020-04-22	Voyager Therapeutics, Inc.	COMPOSITIONS FOR TREATING A DISEASE
AU2017335771A1 (en)	2016-09-28	2019-02-28	Musc Foundation For Research Development	Antibodies that bind interleukin-2 and uses thereof
NZ754606A (en) *	2016-12-23	2023-06-30	Cephalon Llc	Anti-il-5 antibodies
BR112019018915A2 (pt)	2017-03-15	2020-04-14	Pandion Therapeutics Inc	imunotolerância direcionada
JP2020521452A (ja)	2017-05-24	2020-07-27	パンディオン・セラピューティクス・インコーポレイテッド	標的化免疫寛容
EP3630825B1 (en) *	2017-05-25	2024-02-14	Institute For Basic Science	Anti-human interleukin-2 antibodies and uses thereof
US20200299349A1 (en)	2017-11-21	2020-09-24	The Board Of Trustees Of The Leland Stanford Junior University	Partial agonists of interleukin-2
US10946068B2 (en)	2017-12-06	2021-03-16	Pandion Operations, Inc.	IL-2 muteins and uses thereof
US10174091B1 (en)	2017-12-06	2019-01-08	Pandion Therapeutics, Inc.	IL-2 muteins
USRE50550E1 (en)	2017-12-06	2025-08-26	Pandion Operations, Inc.	IL-2 muteins and uses thereof
KR102909650B1 (ko) *	2018-03-13	2026-01-08	터스크 테라퓨틱스 리미티드	종양 특이적 세포 고갈에 대한 항-cd25
MX2021008958A (es) *	2019-02-01	2021-11-04	Regeneron Pharma	Proteínas de unión a antígeno del receptor gamma anti-il2.
AU2020252119B2 (en) *	2019-03-29	2025-09-04	Centre National De La Recherche Scientifique - Cnrs	Interleukin-2 variants with modified biological activity
US12605463B2 (en)	2019-04-12	2026-04-21	The Johns Hopkins University	Tolerogenic artificial antigen-presenting cells
EP3952913A4 (en) *	2019-04-12	2023-05-10	The Johns Hopkins University	Tolerogenic artificial antigen-presenting cells
WO2020236875A1 (en)	2019-05-20	2020-11-26	Pandion Therapeutics, Inc.	Madcam targeted immunotolerance
CN114286687A (zh) *	2019-06-26	2022-04-05	约翰霍普金斯大学	用于靶向扩增调节性t细胞的方法和材料
US20220259298A1 (en) *	2019-07-12	2022-08-18	Kyoto University	Neutralizing Antibody for Tooth Regeneration Treatment Targeting USAG-1 Molecule
CN115768483A (zh)	2020-01-13	2023-03-07	西纳福克斯股份有限公司	抗体与免疫细胞衔接器的缀合物
EP4090674A4 (en)	2020-01-14	2024-01-24	Synthekine, Inc.	Biased il2 muteins methods and compositions
US11981715B2 (en)	2020-02-21	2024-05-14	Pandion Operations, Inc.	Tissue targeted immunotolerance with a CD39 effector
KR20220143869A (ko) *	2020-02-21	2022-10-25	지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드	항-il-2 항체, 이의 항원-결합 단편 및 이의 의학적 용도
CA3176357A1 (en) *	2020-04-24	2021-10-28	Tara M. STRUTT	Cd25-targeted il-2 for increasing cd4 t cell formation and treatment of infections
CN116783213A (zh) *	2020-08-18	2023-09-19	苏黎世大学	Cd25偏向的抗il‐2抗体
KR20230048151A (ko) *	2020-08-18	2023-04-10	유니버시타트 취리히	Cd25 편향된 항-il-2 항체
CN117157107A (zh)	2021-02-08	2023-12-01	西纳福克斯股份有限公司	多功能抗体
EP4130038A1 (en) *	2021-08-03	2023-02-08	Institut national de recherche pour l'agriculture, l'alimentation et l'environnement	Anti-il-2 antibody, complex comprising it, and uses thereof
TW202327642A (zh) *	2021-08-25	2023-07-16	大陸商江蘇恆瑞醫藥股份有限公司	一種含融合蛋白的醫藥組成物
MX2024002476A (es) *	2021-08-27	2024-05-20	Janssen Biotech Inc	Anticuerpos anti-psma y usos de estos.
WO2023061005A1 (zh) *	2021-10-14	2023-04-20	徕特康(苏州)生物制药有限公司	新型抗体-细胞因子融合蛋白及其制备方法和用途
US20250082571A1 (en) *	2021-12-23	2025-03-13	Arizona Board Of Regents On Behalf Of Arizona State University	Compositions and methods for delivery of il-2 and anti-il-2 for treatment of rheumatoid arthritis
CN115850471B (zh) *	2022-10-13	2026-04-07	深圳市百士通科技开发有限公司	一种抗人il-2单克隆抗体及其应用
WO2025032158A1 (en)	2023-08-08	2025-02-13	Institut National de la Santé et de la Recherche Médicale	Method to treat tauopathies
CN120329440A (zh) *	2024-01-18	2025-07-18	烁微生物医药(上海)有限公司	特异性结合hEGFR的单克隆抗体及双特异性抗体
CN118515762B (zh) *	2024-07-23	2024-11-01	北京百普赛斯生物科技股份有限公司	特异性结合il-2的抗体及其应用

Family Cites Families (108)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2413974A1 (fr)	1978-01-06	1979-08-03	David Bernard	Sechoir pour feuilles imprimees par serigraphie
ATE37983T1 (de)	1982-04-22	1988-11-15	Ici Plc	Mittel mit verzoegerter freigabe.
US4522811A (en)	1982-07-08	1985-06-11	Syntex (U.S.A.) Inc.	Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US5807715A (en)	1984-08-27	1998-09-15	The Board Of Trustees Of The Leland Stanford Junior University	Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5128326A (en)	1984-12-06	1992-07-07	Biomatrix, Inc.	Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
US4754065A (en)	1984-12-18	1988-06-28	Cetus Corporation	Precursor to nucleic acid probe
US4683202A (en)	1985-03-28	1987-07-28	Cetus Corporation	Process for amplifying nucleic acid sequences
US4683195A (en)	1986-01-30	1987-07-28	Cetus Corporation	Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5374548A (en)	1986-05-02	1994-12-20	Genentech, Inc.	Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es)	1985-06-26	1992-08-01	Liposome Co Inc	Metodo para acoplamiento de liposomas.
US4676980A (en)	1985-09-23	1987-06-30	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Target specific cross-linked heteroantibodies
US4777127A (en)	1985-09-30	1988-10-11	Labsystems Oy	Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
GB8601597D0 (en)	1986-01-23	1986-02-26	Wilson R H	Nucleotide sequences
US4800159A (en)	1986-02-07	1989-01-24	Cetus Corporation	Process for amplifying, detecting, and/or cloning nucleic acid sequences
GB8702816D0 (en)	1987-02-07	1987-03-11	Al Sumidaie A M K	Obtaining retrovirus-containing fraction
US5219740A (en)	1987-02-13	1993-06-15	Fred Hutchinson Cancer Research Center	Retroviral gene transfer into diploid fibroblasts for gene therapy
WO1988007089A1 (en)	1987-03-18	1988-09-22	Medical Research Council	Altered antibodies
US4880078A (en)	1987-06-29	1989-11-14	Honda Giken Kogyo Kabushiki Kaisha	Exhaust muffler
US5422120A (en)	1988-05-30	1995-06-06	Depotech Corporation	Heterovesicular liposomes
AP129A (en)	1988-06-03	1991-04-17	Smithkline Biologicals S A	Expression of retrovirus gag protein eukaryotic cells
US5047335A (en)	1988-12-21	1991-09-10	The Regents Of The University Of Calif.	Process for controlling intracellular glycosylation of proteins
US5530101A (en) *	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
JP2752788B2 (ja)	1989-01-23	1998-05-18	カイロンコーポレイション	感染および過剰増殖障害の為の組換え療法
ES2116269T3 (es)	1989-03-21	1998-07-16	Vical Inc	Expresion de secuencias exogenas de polinucleotidos en un vertebrado.
US5703055A (en)	1989-03-21	1997-12-30	Wisconsin Alumni Research Foundation	Generation of antibodies through lipid mediated DNA delivery
US6673776B1 (en)	1989-03-21	2004-01-06	Vical Incorporated	Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human
US5108921A (en)	1989-04-03	1992-04-28	Purdue Research Foundation	Method for enhanced transmembrane transport of exogenous molecules
ES2096590T3 (es)	1989-06-29	1997-03-16	Medarex Inc	Reactivos biespecificos para la terapia del sida.
JP4041535B2 (ja)	1989-08-18	2008-01-30	オックスフォードバイオメディカ（ユーケー）リミテッド	標的細胞にベクター構造体を運搬する組換レトロウィルス
US5585362A (en)	1989-08-22	1996-12-17	The Regents Of The University Of Michigan	Adenovirus vectors for gene therapy
WO1991005548A1 (en)	1989-10-10	1991-05-02	Pitman-Moore, Inc.	Sustained release composition for macromolecular proteins
WO1991006287A1 (en)	1989-11-06	1991-05-16	Enzytech, Inc.	Protein microspheres and methods of using them
ZA911974B (en)	1990-03-21	1994-08-22	Res Dev Foundation	Heterovesicular liposomes
US5427908A (en)	1990-05-01	1995-06-27	Affymax Technologies N.V.	Recombinant library screening methods
US5278299A (en)	1991-03-18	1994-01-11	Scripps Clinic And Research Foundation	Method and composition for synthesizing sialylated glycosyl compounds
WO1992019244A2 (en)	1991-05-01	1992-11-12	Henry M. Jackson Foundation For The Advancement Of Military Medicine	A method for treating infectious respiratory diseases
EP0586505A1 (en)	1991-05-14	1994-03-16	Repligen Corporation	Heteroconjugate antibodies for treatment of hiv infection
GB9115364D0 (en)	1991-07-16	1991-08-28	Wellcome Found	Antibody
JP3534749B2 (ja)	1991-08-20	2004-06-07	アメリカ合衆国	アデノウイルスが介在する胃腸管への遺伝子の輸送
AU669124B2 (en)	1991-09-18	1996-05-30	Kyowa Hakko Kirin Co., Ltd.	Process for producing humanized chimera antibody
AU665025B2 (en)	1991-09-23	1995-12-14	Cambridge Antibody Technology Limited	Production of chimeric antibodies - a combinatorial approach
ES2136092T3 (es)	1991-09-23	1999-11-16	Medical Res Council	Procedimientos para la produccion de anticuerpos humanizados.
WO1993010218A1 (en)	1991-11-14	1993-05-27	The United States Government As Represented By The Secretary Of The Department Of Health And Human Services	Vectors including foreign genes and negative selective markers
WO1993010260A1 (en)	1991-11-21	1993-05-27	The Board Of Trustees Of The Leland Stanford Junior University	Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases
GB9125623D0 (en)	1991-12-02	1992-01-29	Dynal As	Cell modification
US5912015A (en)	1992-03-12	1999-06-15	Alkermes Controlled Therapeutics, Inc.	Modulated release from biocompatible polymers
FR2688514A1 (fr)	1992-03-16	1993-09-17	Centre Nat Rech Scient	Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
US5733743A (en)	1992-03-24	1998-03-31	Cambridge Antibody Technology Limited	Methods for producing members of specific binding pairs
EP0650370A4 (en)	1992-06-08	1995-11-22	Univ California	METHODS AND COMPOSITIONS TARGETED ON SPECIFIC TISSUES.
CA2137361A1 (en)	1992-06-10	1993-12-23	W. French Anderson	Vector particles resistant to inactivation by human serum
GB2269175A (en)	1992-07-31	1994-02-02	Imperial College	Retroviral vectors
EP0656064B1 (en)	1992-08-17	1997-03-05	Genentech, Inc.	Bispecific immunoadhesins
AU680459B2 (en)	1992-12-03	1997-07-31	Genzyme Corporation	Gene therapy for cystic fibrosis
US5934272A (en)	1993-01-29	1999-08-10	Aradigm Corporation	Device and method of creating aerosolized mist of respiratory drug
PT695169E (pt)	1993-04-22	2003-04-30	Skyepharma Inc	Lipossomas multivesiculares de ciclodextrina encapsulando compostos farmacologicos e metodos para a sua utilizacao
US5885573A (en)	1993-06-01	1999-03-23	Arch Development Corporation	Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
ES2249761T3 (es)	1993-06-24	2006-04-01	Advec Inc.	Vectores de adenovirus para terapia genica.
ES2328424T3 (es)	1993-09-15	2009-11-12	Novartis Vaccines And Diagnostics, Inc.	Vectores de alfavirus recombinantes.
US6015686A (en)	1993-09-15	2000-01-18	Chiron Viagene, Inc.	Eukaryotic layered vector initiation systems
EP1637608B1 (en)	1993-10-25	2009-07-22	CANJI, Inc.	Recombinant adenoviral vector and methods of use
PT729351E (pt)	1993-11-16	2000-12-29	Skyepharma Inc	Vesiculas com libertacao controlada de activos
US6436908B1 (en)	1995-05-30	2002-08-20	Duke University	Use of exogenous β-adrenergic receptor and β-adrenergic receptor kinase gene constructs to enhance myocardial function
WO1995030763A2 (en)	1994-05-09	1995-11-16	Chiron Viagene, Inc.	Retroviral vectors having a reduced recombination rate
US6132764A (en)	1994-08-05	2000-10-17	Targesome, Inc.	Targeted polymerized liposome diagnostic and treatment agents
AU4594996A (en)	1994-11-30	1996-06-19	Chiron Viagene, Inc.	Recombinant alphavirus vectors
EP0805678B1 (en)	1995-01-05	2003-10-29	THE BOARD OF REGENTS acting for and on behalf of THE UNIVERSITY OF MICHIGAN	Surface-modified nanoparticles and method of making and using same
US6019968A (en)	1995-04-14	2000-02-01	Inhale Therapeutic Systems, Inc.	Dispersible antibody compositions and methods for their preparation and use
US6265150B1 (en)	1995-06-07	2001-07-24	Becton Dickinson & Company	Phage antibodies
EP0850051A2 (en)	1995-08-31	1998-07-01	Alkermes Controlled Therapeutics, Inc.	Composition for sustained release of an agent
DK0885002T3 (da)	1996-03-04	2011-08-22	Penn State Res Found	Materialer og fremgangsmåder til forøgelse af cellulær internalisering
WO1997042338A1 (en)	1996-05-06	1997-11-13	Chiron Corporation	Crossless retroviral vectors
US5874064A (en)	1996-05-24	1999-02-23	Massachusetts Institute Of Technology	Aerodynamically light particles for pulmonary drug delivery
US5855913A (en)	1997-01-16	1999-01-05	Massachusetts Instite Of Technology	Particles incorporating surfactants for pulmonary drug delivery
US5985309A (en)	1996-05-24	1999-11-16	Massachusetts Institute Of Technology	Preparation of particles for inhalation
US6056973A (en)	1996-10-11	2000-05-02	Sequus Pharmaceuticals, Inc.	Therapeutic liposome composition and method of preparation
DE69732306T2 (de)	1997-01-16	2006-01-12	Massachusetts Institute Of Technology, Cambridge	Zubereitung von partikelhaltigen arzneimitteln zur inhalation
US5989463A (en)	1997-09-24	1999-11-23	Alkermes Controlled Therapeutics, Inc.	Methods for fabricating polymer-based controlled release devices
WO1999018792A1 (en)	1997-10-10	1999-04-22	Johns Hopkins University	Gene delivery compositions and methods
SE512663C2 (sv)	1997-10-23	2000-04-17	Biogram Ab	Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
GB9809951D0 (en)	1998-05-08	1998-07-08	Univ Cambridge Tech	Binding molecules
CA2336139C (en)	1998-06-24	2008-10-14	Advanced Inhalation Research, Inc.	Large porous particles emitted from an inhaler
EP1105427A2 (en)	1998-08-17	2001-06-13	Abgenix, Inc.	Generation of modified molecules with increased serum half-lives
HU230769B1 (hu)	1999-01-15	2018-03-28	Genentech Inc.	Módosított effektor-funkciójú polipeptid-változatok
US6737056B1 (en)	1999-01-15	2004-05-18	Genentech, Inc.	Polypeptide variants with altered effector function
US6902734B2 (en) *	2000-08-07	2005-06-07	Centocor, Inc.	Anti-IL-12 antibodies and compositions thereof
US8188231B2 (en)	2002-09-27	2012-05-29	Xencor, Inc.	Optimized FC variants
US7317091B2 (en)	2002-03-01	2008-01-08	Xencor, Inc.	Optimized Fc variants
US20040132101A1 (en)	2002-09-27	2004-07-08	Xencor	Optimized Fc variants and methods for their generation
US20060235208A1 (en)	2002-09-27	2006-10-19	Xencor, Inc.	Fc variants with optimized properties
WO2004029207A2 (en)	2002-09-27	2004-04-08	Xencor Inc.	Optimized fc variants and methods for their generation
CN101014364B (zh)	2002-12-24	2012-01-18	里纳特神经系统学公司	抗ngf抗体及其使用方法
US8084582B2 (en)	2003-03-03	2011-12-27	Xencor, Inc.	Optimized anti-CD20 monoclonal antibodies having Fc variants
RS53984B1 (sr) *	2003-12-10	2015-10-30	E. R. Squibb & Sons L.L.C.	Ip-10 antitela i njihove upotrebe
DK2311873T3 (en) *	2004-01-07	2018-11-26	Novartis Vaccines & Diagnostics Inc	M-CSF-SPECIFIC MONOCLONAL ANTIBODY AND APPLICATIONS THEREOF
US8435517B2 (en)	2008-09-17	2013-05-07	Xencor, Inc.	Compositions and methods for treating IgE-mediated disorders
CU23297A1 (es) *	2004-11-16	2008-07-24	Ct De Inmunologa A Molecular	Formulaciones inmunoterapã0/00uticas para la inducciã"n de autoanticuerpos bloqueadores de la uniã"n de interleucina-2 a su receptor. su uso en el tratamiento del cã ncer
CA2602663A1 (en)	2005-03-31	2006-10-05	Xencor, Inc.	Fc variants with optimized properties
WO2006113546A2 (en)	2005-04-15	2006-10-26	Neogenix Oncology, Inc.	Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
NZ563213A (en) *	2005-06-01	2009-07-31	Micromet Ag	Anti-IL2 antibodies
WO2007041635A2 (en)	2005-10-03	2007-04-12	Xencor, Inc.	Fc variants with optimized fc receptor binding properties
WO2007095643A2 (en)	2006-02-16	2007-08-23	Nascent Biologics, Inc.	Methods for improving immune function and methods for prevention or treatment of disease in a mammalian subject
PL2383297T3 (pl)	2006-08-14	2013-06-28	Xencor Inc	Zoptymalizowane przeciwciała ukierunkowane na CD19
CA2693053C (en)	2007-05-30	2021-01-05	Xencor, Inc.	Methods and compositions for inhibiting cd32b expressing cells
CA2879982C (en)	2012-07-25	2020-09-01	Sarcode Bioscience Inc.	Lfa-1 inhibitor and polymorph thereof
WO2014028748A1 (en) *	2012-08-15	2014-02-20	Irm Llc	Interleukin 2 antibodies and antibody complexes
WO2015109212A1 (en) *	2014-01-17	2015-07-23	Pfizer Inc.	Anti-il-2 antibodies and compositions and uses thereof
KR102876923B1 (ko)	2015-10-23	2025-10-28	화이자 인코포레이티드	항-il-2 항체 및 조성물 및 이의 용도

2016
- 2016-10-21 KR KR1020187014579A patent/KR102876923B1/ko active Active
- 2016-10-21 CA CA2946113A patent/CA2946113A1/en active Pending
- 2016-10-21 AU AU2016340989A patent/AU2016340989B2/en active Active
- 2016-10-21 JP JP2018520536A patent/JP7030689B2/ja active Active
- 2016-10-21 CN CN202210747267.1A patent/CN115636880A/zh active Pending
- 2016-10-21 EP EP16791214.6A patent/EP3365369A1/en active Pending
- 2016-10-21 US US15/331,038 patent/US10138298B2/en active Active
- 2016-10-21 WO PCT/US2016/058249 patent/WO2017070561A1/en not_active Ceased
- 2016-10-21 CN CN201680068098.1A patent/CN109071648B/zh active Active
- 2016-10-21 KR KR1020257035154A patent/KR20250154564A/ko active Pending
- 2016-10-21 TW TW105134200A patent/TW201722989A/zh unknown
2018
- 2018-09-18 US US16/133,939 patent/US10738113B2/en active Active
2020
- 2020-07-09 US US16/925,227 patent/US11459385B2/en active Active
2022
- 2022-09-16 US US17/946,941 patent/US12595301B2/en active Active
2023
- 2023-08-24 AU AU2023219940A patent/AU2023219940A1/en active Pending

Publication	Publication Date	Title
JP2018537962A5 (2)	2019-11-28
JP7379561B2 (ja)	2023-11-14	キメラ抗原及びｔ細胞受容体、並びに使用方法
JP7386382B2 (ja)	2023-11-27	キメラ抗原受容体及びｔ細胞受容体並びに使用方法
CN106967172B (zh)	2019-01-08	抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途
JP7366543B2 (ja)	2023-10-23	Ｂｃｍａ結合分子及びその使用方法
JP2022180371A (ja)	2022-12-06	γδＴ細胞集団の選択的増殖方法及びその組成物
JP6908591B2 (ja)	2021-07-28	Ｉｌ２ｒベータ／共通ガンマ鎖抗体
JP6866294B2 (ja)	2021-04-28	抗ｐｄ−ｌ１抗体
JP7269249B2 (ja)	2023-05-08	Ｉｌ２ｒベータ／共通ガンマ鎖抗体
JP7146394B2 (ja)	2022-10-04	ガレクチン－９に対して方向づけられ、制御性ｔリンパ球の抑制活性の阻害剤である抗体
CN110066338B (zh)	2024-04-09	作为T细胞衔接器的双特异性IgG抗体
CN112512551A (zh)	2021-03-16	双功能蛋白及其构建
RU2019113790A (ru)	2020-11-13	Анти-lag-3 антитела и их композиции
CN107949571A (zh)	2018-04-20	调控免疫反应的方法及抗体
RU2018106364A (ru)	2019-08-22	Антитела против рецептора tfr и их применение при лечении пролиферативных и воспалительных расстройств
JP2023071889A (ja)	2023-05-23	Ｔｉｇｉｔおよびｐｄ－１／ｔｉｇｉｔ結合分子
JP2018512170A5 (2)	2019-04-25
CN112739715A (zh)	2021-04-30	抗cd38抗体的皮下给药
CN121064331A (zh)	2025-12-05	抗btla抗体
RU2013106217A (ru)	2014-09-10	Гибридный белок из антитела против мнс и противовирусного цитокина
EP3946451A1 (en)	2022-02-09	Fibroblast activation protein binding agents and use thereof
US10981996B1 (en)	2021-04-20	Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use
AU2018370120A1 (en)	2020-06-25	Methods for selective expansion of d3 yd T-cell populations and compositions thereof
JP6845237B2 (ja)	2021-03-17	抗−ヒトｉｌ−３抗体、ｉｌ−３の高められた発現又はレベルに関連する疾患又は機能障害へのそれらの使用、及びヒトｉｌ−３の検出方法へのそれらの使用
CN117157323A (zh)	2023-12-01	新型多特异性抗体